Author:
Chen Yongxing,Jin Chenxin,Cui Jiaxue,Diao Yizhuo,Wang Ruiqi,Xu Rongxuan,Yao Zhihan,Wu Wei,Li Xiaofeng
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,General Medicine
Reference58 articles.
1. Adams S, Gatti-Mays ME, Kalinsky K, Korde LA, Sharon E, Amiri-Kordestani L et al (2019) Current landscape of immunotherapy in breast cancer: a review. JAMA Oncol 5(8):1205–1214
2. Cao D, Xu H, Xu X, Guo T, Ge W (2019) High tumor mutation burden predicts better efficacy of immunotherapy: a pooled analysis of 103078 cancer patients. OncoImmunology 8(9):e1629258
3. CD36-mediated ferroptosis dampens intratumoral CD8+ T cell effector function and impairs their antitumor ability - PubMed [Internet]. [cited 2023 May 28]. Available from: https://pubmed.ncbi.nlm.nih.gov/33691090/
4. Cella D, Motzer RJ, Suarez C, Blum SI, Ejzykowicz F, Hamilton M et al (2022) Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial. Lancet Oncol 23(2):292–303
5. De novo induction of intratumoral lymphoid structures and vessel normalization enhances immunotherapy in resistant tumors | Nature Immunology [Internet]. [cited 2023 May 28]. Available from: https://www.nature.com/articles/ni.3836
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献